Background: Vaccine has potential to cause severe cardiac complications. Takotsubo cardiomyopathy (TCM) induced by vaccine is a life-threatening complication, albeit rarely reported. Our study provides a comprehensive insight into this patient cohort on a large scale. Methods: We conducted a systemic literature search in PubMed and EMBASE up to January 5, 2024, using MeSH terms for "vaccine" and "takotsubo cardiomyopathy" to identify cases of vaccine-induced TCM (Figure 1). Results: Our study included 25 cases of TCM with a median age of 63 ± 18.28 years. Of those, 80% were female. TCM was reported in patients after the coronavirus virus 2019 (COVID-19) vaccine (92%) and influenza vaccine (8%). Of COVID-19 vaccines, 88% were mRNA (Moderna, Pfizer) types. Most TCM cases were reported after 2nd dose of vaccine (44%). Chest pain (56%) and dyspnea (44%) were the most common symptoms, with a median time of 3 ± 2.02 days from vaccination to the first symptom onset. Cardiac troponins were elevated in 92% of patients, and ST-segment change (76%) was the most common ECG finding. All patients had left ventricular ejection fraction (LVEF) of 50%, with severe cardiomyopathy (EF 30%) in 24%. LV dysfunction was the most common finding (88%) on echocardiogram. A total of 92% of patients were discharged with improved symptoms after a median length of hospital stay of 7 ± 3.42 days (Figure 2). Conclusion: Although very rare, TCM is a life-threatening complication of vaccine. TCM should be included in the differential diagnosis of patients presenting with post-vaccination chest pain or dyspnea, especially after mRNA vaccines, warranting continued surveillance and regulated reporting of vaccine-related cardiac complications.